Abbreviations
ASCO, American Society of Clinical Oncolog y; EGFR, epidermal growth factor;
NSCLC, non-small cell lung cancer; OH (CCO), Ontario Health (Cancer Care Ontario);
TKI, tyrosine kinase inhibitor
Source
Singh N, Temin S, Baker, Jr. S, et al. erapy for Stage IV Non-Small Cell Lung Cancer
With Driver Alterations Treatment: ASCO Guideline Update. J Clin Oncol. 2022 Jan 28.
doi: 10.1200/JCO.22.00824
Hanna NH, et al. erapy for Stage IV Non-Small Cell Lung Cancer with Driver
Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2021 Feb 16.
doi: 10.1200/JCO.20.03570
e guideline was a cooperative effort among the American Society of Clinical Oncolog y
and Ontario Health (Cancer Care Ontario).
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
ASCOLUND04222a
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
thoracic-cancer-guidelines. Copyright © 2022 by American Society of Clinical Oncolog y.
All rights reserved.
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/thoracic-cancer-guidelines.